









Markets
/
Stocks
/
nasdaq-abt
/

Abbott Laboratories

ABT

131.786USD

-1.944-1.45%

Market hours （ET）Quotes delayed by 15 min

229.37BMarket Cap

16.41P/E TTM



Abbott Laboratories

131.786

-1.944-1.45%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-12

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

4 / 207

Overall Ranking

73 / 4724

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 31 analysts

Buy

Current Rating

141.510

Target Price

+5.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.

Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 93.31.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 29.13%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 29.13%.

Undervalued

The company’s latest PE is 16.65, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.41B shares, increasing 0.49% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 172.03M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-12

The company's current financial score is 7.76, which is higher than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 10.36B, representing a year-over-year increase of 3.95%, while its net profit experienced a year-over-year increase of 8.16%.

Score

Industry at a Glance

Previous score

7.76

Change



Financials

8.01

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.64

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.08

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.65

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-12

The company’s current valuation score is 4.80, which is higher than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 16.36, which is 109.09% below the recent high of 34.21 and -47.35% above the recent low of 24.11.

Score

Industry at a Glance

Previous score

4.50

Change

-0.07

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 4/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-12

The company’s current earnings forecast score is 7.87, which is higher than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Abbott Laboratories is 142.56, with a high of 159.00 and a low of 122.15.

Score

Industry at a Glance

Previous score

7.87

Change

Support & Resistance

No Data

Analyst Rating

Based on 31 analysts

Buy

Current Rating

141.510

Target Price

+5.82%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Abbott Laboratories

ABT

Medtronic PLC

MDT

Stryker Corp

SYK

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

Insulet Corp

PODD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-12

The company’s current price momentum score is 8.89, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 135.62 and the support level at 126.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.75

Change

2.25

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.047

Buy

RSI(14)

57.257

Neutral

STOCH(KDJ)(9,3,3)

70.489

Buy

ATR(14)

2.124

High Vlolatility

CCI(14)

139.629

Buy

Williams %R

16.367

Overbought

TRIX(12,20)

0.062

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

131.978

Sell

MA10

132.194

Sell

MA20

131.926

Sell

MA50

130.436

Buy

MA100

131.762

Buy

MA200

127.986

Buy

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 81.28%, representing a quarter-over-quarter decrease of 0.16%. The largest institutional shareholder is The Vanguard, holding a total of 172.03M shares, representing 9.88% of shares outstanding, with 2.11% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

169.07M

+0.70%

BlackRock Institutional Trust Company, N.A.

87.82M

+0.86%

State Street Global Advisors (US)

77.66M

+0.64%

Capital International Investors

66.82M

-1.69%

Capital Research Global Investors

50.73M

-6.22%

Geode Capital Management, L.L.C.

36.90M

+3.46%

JP Morgan Asset Management

28.80M

+14.58%

Wellington Management Company, LLP

29.76M

+12.77%

Norges Bank Investment Management (NBIM)

20.98M

+3.08%

Wells Fargo Advisors

15.42M

+1.09%

Risk Assessment

Currency: USD Updated：2025-09-12

The company's beta value is 0.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.